VACCINES-EUROPE
21.1.2020 07:37:09 CET | Business Wire | Press release
At an event held in the European Parliament today, policymakers noted the lack of progress made by EU Member States towards the EU’s 75% target for seasonal influenza vaccination coverage rates among older-age and at-risk groupsi , first adopted in the EU Council Recommendation on seasonal influenza vaccination in 2009.ii
Speakers from the European Commission, European Parliament, European Centre for Disease Prevention and Control (ECDC) and World Health Organisation (WHO) all agreed on the need to seize the opportunity presented by the 10-year milestone of the 2009 Recommendation to renew efforts to boost coverage rates and address the major public health challenges associated with seasonal influenza.
Building on a new study on public perceptions of seasonal influenza disease and vaccination in four EU countriesiii and leveraging some national best practices, panellists stressed the need for all influenza stakeholders to gather in simultaneously addressing influenza vaccine confidence, convenience and complacency issues.
Potential solutions were discussed and identified, which would help addressing specific challenges and make progress towards the ten-year-old 75% seasonal influenza vaccination target, such as:
- Voluntary exchange of best practices between EU countries on how to increase seasonal influenza vaccination rates. This could be done as part of the EU State of Health initiative cycle.iv Following the publication of Country Health Profiles 2019, the European Commission could establish voluntary exchanges between EU countries, in particular focusing on seasonal influenza vaccination policies and programmesv .
- EU guidance on data collection for seasonal influenza vaccine coverage rates. This should cover what should be collected, when and how . Currently, data is collected differently and at different times in various EU Member States, which creates an uneven and patchy picture across the EU. An EU Guidance on data collection will allow to monitor whether the EU’s 75% target has been met in all at risk or targeted groups as well as propose appropriate measures to achieve it.
- Measures to allow all competent healthcare professionals to provide vaccination in convenient locations. For example, by allowing vaccine administration in locations such as workplaces, community pharmacies and schools. Evidence shows that in countries where pharmacists can administer vaccines, the number of people vaccinated increases.vi The EU has a role to play in sharing best practices and providing guidance, and EU Member States will need to introduce appropriate legislations and policies to implement these practices.
- Further work by EU Member States, as well as the EU and WHO, needs to improve knowledge/education of and confidence in, vaccines among both citizens and healthcare professionals. In some countries, as many as 36.4% of GPs do not believe that the seasonal influenza vaccination is important, and elsewhere the percentage of the general public who believe that it is important is as low as 40.4%. Countries such as Spain and Portugal showcase best practices, with public confidence rates of almost 80%.vii
- All influenza actors should join forces in, for example, a multi-stakeholder coalitionviii , and launch an European Influenza Awareness Day , that would help to boost influenza vaccination confidence.
MEP Dolors Montserrat (EPP, ES), co-host of the event and former Spanish Health Minister, said that “to progress towards a broader vaccination coverage, especially for people with chronic diseases, we need to:
- Raise awareness among healthcare professionals, and policy makers on the problem to build trust in institutions and providers of vaccines;
- Empower patients to be correctly informed and participate in the decision making process on the adequate and most cost-effective therapies for their health;
- Fight the fake news and the misinformation campaigns through promoting sources of reliable information about vaccination, exposure to positive media messages.”
“The EU has given vaccination a lot of political attention recently – not least through the 2018 Council Recommendation on Strengthened Cooperation Against Vaccine-Preventable Diseases, the EU Joint Action on Vaccination, and the 2019 Global Vaccination Summit. But dwindling seasonal influenza vaccination coverage rates show that much more needs to be done – both at EU and national level” said Magdalena R. de Azero, Executive Director of Vaccines Europe, which organised the event. Ms de Azero concluded: “This event underlines the need for institutions, governments, healthcare professionals and industry to work together to address this challenge.”
Notes
Seasonal influenza poses a significant but often under-recognised challenge to EU health systems. Compared to other infectious diseases, it has the highest impact in terms of mortality and incidence and is estimated to cause up to 70,000 deaths in the EU each year, particularly among older age groups.ixx Its impact is particularly acute among the elderly and other at-risk groups.
Latest EU data (2017, published in 2019) shows that no EU Member State has reached the 75% target for coverage rates. In fact, many countries have seen rates decline, some going as low as single digits (Latvia 6.9%, Estonia 4.8%). The best-in-class EU country, the UK, has seen rates consistently around 70% in recent years (currently 72.6%).xi
About Vaccines Europe
Formed in 1991, Vaccines Europe is a specialised group of the European Federation of Pharmaceutical Industries and Associations (EFPIA) that represents major innovative research-based vaccine companies as well as small and medium-sized enterprises operating in Europe which account for a large share of human vaccines used worldwide.
i
As defined by ECDC. https://www.ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/vaccines/risk-groups
ii
https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:348:0071:0072:EN:PDF
iii
Full study to be published in the near future. Presented by Professor Frederic Bouder of the University of Stavanger.
iv
https://ec.europa.eu/health/state/summary_en
v
https://ec.europa.eu/health/sites/health/files/vaccination/docs/2018_vaccine_services_en.pdf
.
vi
https://www.vaccinestoday.eu/stories/does-pharmacy-vaccination-increase-overall-uptake/
vii
https://ec.europa.eu/health/sites/health/files/vaccination/docs/2018_vaccine_confidence_en.pdf
viii
For example: https://www.immunize.org/
ix
https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2018.23.16.17-00454
x
https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet
xi
https://ec.europa.eu/eurostat/web/products-eurostat-news/product/-/asset_publisher/VWJkHuaYvLIN/content/DDN-20191209-2
View source version on businesswire.com: https://www.businesswire.com/news/home/20200120005574/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Unleashing GEN4: a New Era of High-performance, Sustainable Electric Racing Begins21.4.2026 17:54:00 CEST | Press release
The debut of the GEN4 race car underlines a step change in electric racing performance. Set for its competitive debut in the 2026/27 Season, the GEN4 machine has a 71% increase in power. More road-relevant than ever, many of the biggest OEMs will take these innovations from track to road. The Fédération Internationale de l'Automobile (FIA) and Formula E have unleashed the GEN4 car on track in its debut run in the South of France, signalling the beginning of a new era for electric motor sport. This all-new car will be raced in the 2026/27 Season of the ABB FIA Formula E World Championship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421618886/en/ Unleashing GEN4: A new era of high-performance, sustainable electric racing begins Capable of speeds over 335kph (208mph), 0-100kph in approximately 1.8s, and 0-200kph in just 4.4s - 1.5s faster than its predecessor. GEN4 produces up to 600kW of power, a 71% increase in base ou
Resale on the Rise: Klarna's Resell Feature Grows 75% as Consumers Put Real Money Back in Their Pockets21.4.2026 17:00:00 CEST | Press release
New data from Klarna reveals consumers are making an estimated $137 per sold item as resale becomes a go-to financial habit New data from Klarna,the global digital bank and flexible payments provider, reveals that its in-app resell feature is gaining significant momentum:listings created through the app grew by up to 75% over the past 13 months*, as consumers increasingly turn to resale as a way to earn real money from items they already own. The data points to a broader shift in financial behaviour: consumers are increasingly treating the things they own not as fixed costs, but as assets with ongoing value. Reselling is becoming routine, not a one-off First launched in Sweden in 2022, Klarna's resell feature is now available across 15 markets, letting users list items for resale directly from their purchase history via leading resale marketplaces such as eBay, Poshmark and Tradera. No need to remember what they paid, find the receipt, or switch to another app. Klarna pre-fills key lis
Frasca Pilatus PC-12 PRO Flight Training Device Receives FOCA Qualification21.4.2026 16:05:00 CEST | Press release
Training device developed for the Pilatus PC-12 PRO with Garmin’s G3000 PRIME Integrated Flight Deck Frasca International, Inc., a FlightSafety International company and global leader in flight simulation, today announced that its Pilatus PC-12 PRO Flight Simulation Training Device (FSTD) received Level 2 Flight Training Device (FTD2) and Flight and Navigation Procedures Trainer (FNPT II) qualification from Switzerland’s Federal Office of Civil Aviation (FOCA). Frasca is the first to develop a PC-12 PRO training device. The device equipped with Garmin’s G3000 PRIME Avionics suite is installed at Pilatus Aircraft Ltd headquarters in Stans, Switzerland, where it will support training for the next generation of PC-12 pilots. The qualification enables pilots to complete a wide range of instruments, procedural and advanced systems training in a highly immersive environment that mirrors the capabilities of the aircraft. “The PC-12 PRO leads the way with advanced features, and we’re proud to
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting21.4.2026 16:00:00 CEST | Press release
- Data from pivotal frontMIND study of tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) featured in oral presentation at ASCO; results support global regulatory submissions Incyte (Nasdaq:INCY) today announced that full results from the Phase 3 pivotal study evaluating tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) will be featured as an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago. “The positive Phase 3 frontMIND results for tafasitamab in patients with newly diagnosed diffuse large B-cell lymphoma highlight Incyte’s continued focus on advancing novel differentiated approaches with the potential to meaningfully impact patients,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “We look forward to sharing the full data at ASCO, and to progressing our pipeline.” Presentation details:
Wolters Kluwer CCH Tagetik Kicks Off Global inTouch 2026 Series Showcasing Expert AI in Action for the Office of CFO21.4.2026 15:28:00 CEST | Press release
Wolters Kluwer CCH Tagetik is set to host Global inTouch 2026, its flagship user conference which takes place May 19–21, 2026, in Lucca, Italy. Celebrating its 20th edition, Global inTouch launches a global event series demonstrating how CCH Tagetik with Expert AI is transforming the way finance works with AI-enabled capabilities embedded directly into the processes that matter most to the office of the CFO. Following the event in Lucca, the Global inTouch showcase will continue with regional inTouch events across key markets worldwide, including Belgium, France, Germany, Japan, the Netherlands, Sweden, the United Kingdom, and the United States. This year’s theme, Own the Future, reflects Wolters Kluwer CCH Tagetik’s commitment to continuous innovation and to empowering finance teams to deliver impact today while confidently shaping what’s next. “The role of the CFO is expanding from reporting on the past to strategically orchestrating the future to maximize value creation,” saidMaria
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
